View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
January 14, 2021

Genomics and Covid-19: UK’s real-time surveillance system to track viral mutations

Research consortium COG-UK has been coordinating work across the UK to sequence the whole genome of the SARS-CoV-2 virus, which causes Covid-19, to inform public health responses to the country’s epidemic. Allie Nawrat explores COG-UK’s latest project to accelerate and provide real-time surveillance of Covid-19 outbreaks and vaccine deployment.

By Allie Nawrat

The UK has been hit incredibly hard by the Covid-19 pandemic. To date, the country has experienced 3.2 million cases and more than 84,000 deaths related to SARS-CoV-2, the coronavirus causing Covid-19, according to John Hopkins University’s coronavirus resource centre

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Unfortunately, the UK Government’s tiered approach to easing a month-long lockdown in early December failed to curb the spread of the viral pandemic – particularly in London, the East and South East of England. On 14 December, Secretary of State for Health and Social Care, Matt Hancock, revealed that this was probably linked with the emergence of a new variant of SARS-CoV-2 that is spreading significantly faster than existing viral variants. This new variant, and its impact on escalating case numbers, was one of the reasons why the UK had to re-enter lockdown on Tuesday 5 January. 

This new variant of the novel coronavirus, which involves a N501Y mutation in SARS-CoV-2’s spike protein used to infect humans through the ACE2 receptor, was identified through the efforts of UK public health agencies and with the support of the Covid-19 Genomics Consortium UK (COG-UK). Created in late March 2020 with £20m funding from UK Research and Innovation, COG-UK is bringing together researchers from 16 sites across the UK, including the Wellcome Sanger Institute, to sequence positive samples of SARS-CoV-2 to track the emergence of mutations and how they are spreading over time. 

The identification of this new variant using genomics illustrates how crucial whole genome sequencing of SARS-CoV-2 is to inform public health responses to the ongoing Covid-19 pandemic. 

Role of genomic sequencing in Covid-19 response

In mid-January 2020, researchers in China and Australia published the whole genome sequence of a virus that was causing a respiratory disease outbreak in Wuhan, China. Understanding the genomics of what would later be named SARS-CoV-2 enabled governments and researchers to track the emergence of Covid-19 outbreaks in their country. 

For instance, COG-UK director of strategy and transformation Dr Ewan Harrison explains that during the first wave of Covid-19 in the UK, the research consortium was able to figure out that the first importations into the UK came primarily from France and Spain, not Italy or China as many assumed. 

Whole viral genome sequencing also allows for better understanding of the transmission of the virus, including whether it is mutating and becoming a larger threat. In addition, genomics can help to explain why people respond to Covid-19 in different ways, therefore helping to identify and better protect those at greater risk of severe disease.

To do this, according to Harrison, COG-UK has leveraged the UK’s impressive genomics capacity to capture Covid-19 diagnostic test samples from both NHS and Lighthouse labs in order to sequence the viral genomes. The results are then uploaded into COG-UK’s central server where they are analysed to look for the presence of mutations and phylogenies of SARS-CoV-2 in an automated fashion. 

To find out if certain viral variants are linked with more severe diseases, Harrison notes, COG-UK is also linking its viral genome sequences with NHS patient data and a human genome sequencing project being carried out with Genomics England

All the data then flows to those doing research and into the public health agencies responsible for overseeing Covid-19 response, explains Harrison.

Need for real-time surveillance

COG-UK and its partners have been incredibly successful at identifying viral variants to help to understand existing outbreaks. Not only was their work instrumental in understanding the variant responsible for the rapid spread of Covid-19 in the South East of England, but genomics has also been useful to determining the source of highly local outbreaks. Harrison provides the example of Addenbrooke’s Hospital in Cambridge and how COG-UK researchers used genomics to identify the source of a local outbreak as a minibus transporting dialysis patients to and from the hospital. 

However, there is a need for genomics to be able to help public health bodies respond faster to outbreaks as they emerge. To this end, COG-UK and the Sanger Institute have raised £12.2m in funding from the Department of Health and Social Care’s Testing Innovation Fund to create a real-time surveillance system of emerging outbreaks. This system will be supported by new software being developed by the Sanger Institute and involves researchers from across the consortium’s network. 

Instead of relying on epidemiological exceedance, which “often requires a large number of cases to detect” outbreaks, genomics can help identify and respond to large clusters maybe a week earlier, according to Harrison.

This is because, for example, genome sequencing can show there are five identical SARS-CoV-2 viruses within one workplace on the same day, thereby suggesting there is Covid-19 transmission going on in that workplace. “If you didn’t have genomics you might know you had five cases, but you wouldn’t know if they were related” and constituted an outbreak. It is possible that all five cases could be different, meaning they have separate sources and do not represent a cluster. 

However, for a real-time surveillance system to be effective, there is a need to speed up genomics sequencing. This is what COG-UK, the Sanger Institute and all the consortium’s researchers are working on currently. “We are constantly working to reduce the turnaround time for the moment that a sample tests positive to the sequence being generated and uploaded,” notes Harrison. 

Harrison adds: “We have been looking at some outbreaks retrospectively and there is a good chance we could have detected them if we had been sequencing the virus in near real-time.” 

Informing vaccine roll out

Not only will the real-time genomics surveillance support earlier responses to local outbreaks, COG-UK and the Sanger Institute also hope it will allow them to monitor the virus’s response to vaccines and identify any viral mutations associated with vaccine failure. Vaccine failure suggests that the virus has evolved to evade the induced immune response. 

Harrison explains that in the case of vaccine failure, which leads someone to get Covid-19 after being vaccinated, the consortium could sequence the virus and identify any “particular mutations that seem to reduce the ability of an antibody to bind to the virus”. 

This is extremely important as the UK was the first country to emergency approve Pfizer/BioNTech’s mRNA vaccine BNT162b2 and AstraZeneca/University of Oxford’s adenovirus Covid-19 vaccine. The rollout of these vaccines has begun, therefore, if there are any issues with the virus evolving to resist the vaccines, this needs to be known and dealt with as rapidly as possible. 

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU